Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | HEXA | CTRPv2 | pan-cancer | AAC | -0.17 | 5e-07 |
mRNA | PICALM | CTRPv2 | pan-cancer | AAC | -0.17 | 5e-07 |
mRNA | ZNF669 | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-07 |
mRNA | CDCA7 | CTRPv2 | pan-cancer | AAC | 0.18 | 5e-07 |
mRNA | NRF1 | CTRPv2 | pan-cancer | AAC | 0.18 | 5e-07 |
mRNA | FAM171A2 | CTRPv2 | pan-cancer | AAC | 0.19 | 5e-07 |
mRNA | ATL1 | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-07 |
mRNA | MLPH | CTRPv2 | pan-cancer | AAC | -0.18 | 5e-07 |
mRNA | HMGN2 | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-07 |
mRNA | GPR137C | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-07 |